Breakthrough in RNA Medicine: Small-Molecule Inhibitors Developed Against RNA-Modifying Enzyme METTL16

Discover the groundbreaking research at the Chemical Genomics Center at the Max Planck Institute of Molecular Physiology in Dortmund, where scientists have developed the first small-molecule inhibitors against the RNA-modifying enzyme METTL16. This significant breakthrough paves the way for the development of therapeutic agents targeting RNA modifiers, bringing us closer to understanding the role of RNA in health and disease.